Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial.
The prophylactic efficacy of WR 238605, a primaquine analog, was studied with a human Plasmodium falciparum challenge model. A single oral dose of 600 mg, administered 1 day prior to challenge, successfully protected three of four subjects. The fourth subject developed mild, oligosymptomatic malaria on day 31, with drug concentrations one-half of those in the protected individuals. WR 238605 appears to be a promising prophylactic drug for P. falciparum malaria.
Brueckner
R P
RP
Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA. LTC_Ralf_Brueckner@WRSMTP-ccMail.Army.Mil
Coster
T
T
Wesche
D L
DL
Shmuklarsky
M
M
Schuster
B G
BG
D000328:Adult; D000634:Aminoquinolines / Q000737:chemistry / Q000627:therapeutic use*; D000818:Animals; D000962:Antimalarials / Q000737:chemistry / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D016778:Malaria, Falciparum / Q000517:prevention & control*; D008297:Male; D010963:Plasmodium falciparum / Q000187:drug effects* / Q000472:pathogenicity
D000634:Aminoquinolines; D000962:Antimalarials; C055852:tafenoquine; C080436:8-aminoquinoline